A Cell Press partner journal
 
Related commentsú║
í˝ Touristú║anonymous   [11-19]
55% of liver cancer cases in the world come from China.
Add comment (English only)
Name*:
E-mail:
Telephone:
Code:  
Comments*:
 Position: Home > issue > The 2nd Issue  
Therapy of primary liver cancer
Category: Review
Author: Shaokun Shu

╦Đ╣ĚŻě═╝20�?8�?2�?821_5.jpg

Therapy of primary liver cancer


Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the rate of incidence is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC (cHCC-ICC). These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.





[Printing]  [Close
Host:   Academic co-partner: Stay connected:
    SHANGHAI INSTITUTE OF APPLIED PHYSICS, CAS

  inquiry@the-innovation.org
  the.innovation.journal
  the.innovation.journal
  The_InnovationJ
  The Innovation┤┤đ┬
  The Innovation┤┤đ┬

Publishing partner:   INSTITUTE OF MICROBIOLOGY, CAS
  XI'AN INSTITUTE OF OPTICS AND PRECISION MECHANICS, CAS
  Copyright © 2019-2020 the-innovation.org All Rights Reserved